Camurus AB (publ) (STO:CAMX)

Market Cap	35.14B -17.9%
Revenue (ttm)	2.27B +0.0%
Net Income	678.17M -5.6%
EPS	11.31 -6.2%
Shares Out	59.51M
PE Ratio	52.22
Forward PE	28.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,801
Open	594.50
Previous Close	590.50
Day's Range	589.00 - 606.50
52-Week Range	430.80 - 754.50
Beta	0.52
Analysts	Strong Buy
Price Target	793.00 (+33.5%)
Earnings Date	Nov 5, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 316
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CAMX

Financial Performance

In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.

Analyst Summary

According to 7 analysts, the average rating for CAMX stock is "Strong Buy." The 12-month stock price target is kr 793.00, which is an increase of 33.50% from the latest price.

Price Target

kr 793.00

(33.50% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 2, 2026

Data Sources Report a data error